Stockscreener 앱 받기
2.23
3.72%
0.08
시간 외 거래:
2.24
0.01
+0.45%
Alector Inc 주식(ALEC)의 최신 뉴스
Is Alector Inc.’s growth already priced inFree Investment Consultation - mustnews.co.kr
3 Promising Penny Stocks With Market Caps Above $200M - simplywall.st
Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates - MSN
Alector (ALEC): A High-Conviction Biotech Play with Near-Term Catalysts and a Clear Path to Value Creation - AInvest
Alector 2025 Q2 Earnings Continued Losses Despite Narrowing Net Income - AInvest
Transcript : Alector, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Alector's 30% Surge: A Biotech Breakout or a Volatility Trap? - AInvest
Promising Advancements in Alector’s Clinical Trials Highlighted by Positive Biomarker Data and Therapeutic Potential - TipRanks
H.C. Wainwright Maintains Alector(ALEC.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
BofA Securities Maintains Alector(ALEC.US) With Sell Rating, Maintains Target Price $1 - 富途牛牛
Alector Tightens Losses As Analysts Set Sights Higher - Finimize
Earnings call transcript: Alector beats Q2 2025 EPS and revenue forecasts - Investing.com
Alector's Q2 Earnings Call: Promising Progress in Dementia Trials Amidst Strategic Challenges - AInvest
Alector's Promising Future: Buy Rating Backed by FDA-Endorsed Trials and Amendments - AInvest
Alector Inc (ALEC) Q2 2025 Earnings Call Highlights: Promising Advances in Dementia Trials Amidst Strategic Challenges - GuruFocus
Alector Inc (ALEC) Q2 2025 Earnings Call Highlights: Promising A - GuruFocus
Alector Advances Neurodegenerative Therapies Amid Financial Updates - TipRanks
Alector: Q2 Earnings Snapshot - Chron
Promising Developments and Strong Financials Make Alector a Compelling Buy - TipRanks
Alector’s Promising Future: Buy Rating Backed by Strategic Trials and FDA-Endorsed Amendments - TipRanks
Alector (ALEC) Q2 Revenue Falls 48% - The Globe and Mail
Alector earnings beat by $0.17, revenue topped estimates By Investing.com - Investing.com South Africa
Alector sees FY25 revenue view $13M-$18M, consensus $12.56M - TipRanks
Alector earnings beat by $0.17, revenue topped estimates - Investing.com Canada
Alector: A Biotech Gem Navigating the Post-IRA Landscape with Robust Financials and Promising Pipeline - AInvest
Alector Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Alector Nears Crucial Phase 3 Results for First-Ever FTD Treatment as Cash Hits $307M - Stock Titan
Should I hold or sell Alector Inc. stock in 2025Invest smarter with daily stock recommendations - Jammu Links News
What makes Alector Inc. stock price move sharplyBoost your wealth with consistent growth stocks - Jammu Links News
How strong is Alector Inc. company’s balance sheetTremendous wealth creation - Jammu Links News
What institutional investors are buying Alector Inc. stockPowerful profit generation - Jammu Links News
Is Alector Inc. a good long term investmentInvest smarter with actionable market insights - Jammu Links News
How does Alector Inc. generate profit in a changing economyAchieve breakthrough financial results today - Jammu Links News
What is the dividend policy of Alector Inc. stockIdentify undervalued stocks ready to soar - Jammu Links News
What is Alector Inc. company’s growth strategyBuild a diversified portfolio for stability - Jammu Links News
Alector Inc. Stock Analysis and ForecastGet exclusive access to professional stock picks - Jammu Links News
How does Alector Inc. compare to its industry peersDiscover high-impact stocks for growth - Jammu Links News
Is it the right time to buy Alector Inc. stockHigh-yield investments - Jammu Links News
Why is Alector Inc. stock attracting strong analyst attentionAchieve rapid financial growth with smart picks - Jammu Links News
What are analysts’ price targets for Alector Inc. in the next 12 monthsBuild a diversified portfolio for steady profits - Jammu Links News
Alector’s Latozinemab Study: A Promising Step in Neurodegenerative Disease Treatment - The Globe and Mail
How to build a custom watchlist for Alector Inc.Sector Rotation Strategy for Smart Traders - Newser
Market reaction to Alector Inc.’s recent newsRSI and MACD Signal Summary with Trends - Newser
Identifying reversal signals in Alector Inc.Free AI Powered High Return Stock Calls - Newser
Why Alector Inc. stock attracts strong analyst attentionPortfolio Risk Distribution Analysis Tool - Newser
Alector Inc expected to post a loss of 46 cents a shareEarnings Preview - TradingView
Alector's Latozinemab Study Advances Neurodegenerative Disease Treatment - AInvest
When is Alector Inc. stock expected to show significant growthExpert Picks Watchlist For Every Investor - Jammu Links News
What is the risk reward ratio of investing in Alector Inc. stockFinancial News Review For Consistent Profits - Jammu Links News
Risk adjusted return profile for Alector Inc. analyzedReal Chart Based Opportunity Identification - Newser
How to recover losses in Alector Inc. stockShort-Term Stock Trend Forecast Guide - Newser
1.02%
3.70%
자본화:
|
볼륨(24시간):